Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan and Lacidipine QT Interval Study
NCT02264158Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2001
- Primary completion
- Mar 2002
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of telmisartan and lacidipine in hypertension (HTN) (6 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Average QTcF (QT interval Fridericia correction) change at day 7. Started Sep 2001; status: completed.
02
Drugs
telmisartanlacidipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02264158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02264158.